Your session is about to expire
← Back to Search
INTERCEPT Blood System for Blood Transfusion Safety (RedeS Trial)
RedeS Trial Summary
This trial is designed to study the safety and efficacy of the INTERCEPT Blood System for pathogen reduction of red blood cells in comparison to conventional methods. If successful, the system may be made available in areas where transfusion-transmissible infections are common.
RedeS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRedeS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RedeS Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you tell me if this research study is still enrolling individuals?
"From the information available on clinicaltrials.gov, it seems that this particular trial is still looking for volunteers. The original posting date was 5/11/2017, with the most recent edit on 3/2/2022."
How many people total will be participating in this research?
"In order to complete this study, 800 willing and eligible patients are needed. To find patients, the research team is looking at multiple sites including Grady Health System in Atlanta, Georgia and Virginia Commonwealth University in Richmond, Virginia."
Are there any other sites in Canada conducting this clinical trial?
"There are 4 sites currently running this trial, with locations in Atlanta, Richmond, and Dallas, as well as 4 other locations. To minimize strain, patients should choose a location closest to them."
What are researchers looking to discover through this clinical trial?
"The primary outcome that will be observed in patients within 15 minutes to 24 hours post transfusion is the development of treatment emergent antibodies. Additionally, the study will measure secondary outcomes including HbA clearance, RBC allo-antigens, and transfusion reactions related to study RBCs."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
What site did they apply to?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger